Quantitative modeling for drug dosing gets FDA support

beakers

In the world of medicine and pharmaceutical development, optimized drug dosing for individuals remains a challenge. A Colorado State University biomedical researcher has received a grant to improve that process, using a quantitative modeling approach.

Brad Reisfeld, associate professor of chemical and biological engineering and a faculty member in the School of Biomedical Engineering, has been awarded a two-year, $500,000 grant from the U.S. Food and Drug Administration to develop a “population physiologically-based pharmacokinetic model” for drug dosing. The model would allow scientists and drug developers to better understand variability in drug concentrations among individuals in a population.

CSU, other collaborators

The newly funded, two-year study includes CSU collaborator Sudipto Ghosh, an associate professor in computer science; as well as colleagues from France’s National Institute for Industrial Environment and Risks; Texas A and M, and Boise State University.

The team’s long-term goal is to develop a robust, efficient algorithm, integrated into a software platform, for analyzing drug-taking population data. Their approach would harness the predictive power of a pharmacokinetic model to make personalized predictions for dosing. This would ultimately help ensure efficacy and safety of drugs across diverse populations.